[{"id":"c2fb4b7e-7e4c-490d-87bd-2814f4996b26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886049","created_at":"2023-06-02T14:06:05.454Z","updated_at":"2025-02-25T13:55:14.969Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene","source_id_and_acronym":"NCT05886049","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-20"},{"id":"5c523880-f8a6-448f-8403-e3010aefe575","acronym":"","url":"https://clinicaltrials.gov/study/NCT03772925","created_at":"2021-01-18T18:39:51.839Z","updated_at":"2025-02-25T14:40:05.004Z","phase":"Phase 1","brief_title":"Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT03772925","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • CD4","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation","tags":["BCL2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pevonedistat (MLN4924) • Beleodaq (belinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/20/2019","start_date":" 06/20/2019","primary_txt":" Primary completion: 06/16/2025","primary_completion_date":" 06/16/2025","study_txt":" Completion: 06/16/2025","study_completion_date":" 06/16/2025","last_update_posted":"2025-02-14"},{"id":"2215a379-2b74-4e43-b073-534f2995d428","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001788","created_at":"2023-08-21T14:08:48.344Z","updated_at":"2025-02-25T15:13:42.778Z","phase":"Phase 1","brief_title":"Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06001788","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • Komzifti (ziftomenib) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 02/22/2024","start_date":" 02/22/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-13"},{"id":"460f1e61-72a2-48bb-a37c-e804016f6240","acronym":"NCI-2021-06095","url":"https://clinicaltrials.gov/study/NCT05010122","created_at":"2021-08-18T15:53:42.501Z","updated_at":"2025-02-25T15:12:15.219Z","phase":"Phase 1/2","brief_title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05010122 - NCI-2021-06095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-13"},{"id":"e5e2b950-7554-4958-b2db-713f66c51761","acronym":"","url":"https://clinicaltrials.gov/study/NCT03280030","created_at":"2021-01-18T16:11:51.281Z","updated_at":"2025-02-25T15:42:59.213Z","phase":"Phase 2","brief_title":"A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML","source_id_and_acronym":"NCT03280030","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 04/06/2018","start_date":" 04/06/2018","primary_txt":" Primary completion: 11/14/2022","primary_completion_date":" 11/14/2022","study_txt":" Completion: 11/14/2022","study_completion_date":" 11/14/2022","last_update_posted":"2025-02-11"},{"id":"e3936c5c-e8c6-4488-bd75-cc3cc84c9df4","acronym":"NCI-2018-01789","url":"https://clinicaltrials.gov/study/NCT03661307","created_at":"2021-01-18T17:57:55.790Z","updated_at":"2025-02-25T15:25:53.725Z","phase":"Phase 1/2","brief_title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03661307 - NCI-2018-01789","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib) • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-10"},{"id":"b4e91c3d-4887-4ce6-b858-890536bcbb7b","acronym":"HOVON 156 AML","url":"https://clinicaltrials.gov/study/NCT04027309","created_at":"2021-01-18T19:46:07.637Z","updated_at":"2025-02-25T15:26:07.674Z","phase":"Phase 3","brief_title":"A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy","source_id_and_acronym":"NCT04027309 - HOVON 156 AML","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3-TKD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • midostaurin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 777","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 06/01/2033","study_completion_date":" 06/01/2033","last_update_posted":"2024-12-17"},{"id":"a154a323-d6ef-4152-926e-c4ab1ae75b5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756777","created_at":"2023-03-06T15:01:58.629Z","updated_at":"2025-02-25T15:36:05.770Z","phase":"Phase 1","brief_title":"A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05756777","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation","tags":["FLT3 • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-11-12"},{"id":"711f8265-575f-4a14-bb60-be585609d334","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024994","created_at":"2021-08-27T12:53:02.872Z","updated_at":"2025-02-25T13:35:55.158Z","phase":"Phase 2","brief_title":"A Study of E7820 in People With Bone Marrow (Myeloid) Cancers","source_id_and_acronym":"NCT05024994","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation","tags":["FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7820"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-07-03"},{"id":"1d8c8a20-aa7c-47e4-aa25-c755f938afd8","acronym":"LACEWING","url":"https://clinicaltrials.gov/study/NCT02752035","created_at":"2021-01-17T17:23:14.096Z","updated_at":"2024-07-02T16:34:26.721Z","phase":"Phase 3","brief_title":"A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy","source_id_and_acronym":"NCT02752035 - LACEWING","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 183","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-06-12"},{"id":"75104445-162f-444f-84ea-8038034ab832","acronym":"","url":"https://clinicaltrials.gov/study/NCT02727803","created_at":"2021-01-18T13:21:10.406Z","updated_at":"2024-07-02T16:34:36.895Z","phase":"Phase 2","brief_title":"Personalized NK Cell Therapy in CBT","source_id_and_acronym":"NCT02727803","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/19/2016","start_date":" 05/19/2016","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-06-10"},{"id":"3102105e-b831-48d9-b839-01e75ece3f9a","acronym":"COVALENT-103","url":"https://clinicaltrials.gov/study/NCT05918692","created_at":"2023-06-26T14:09:14.079Z","updated_at":"2024-07-02T16:35:00.712Z","phase":"Phase 1","brief_title":"A Phase 1, Study of BMF-500 in Adults With Acute Leukemia","source_id_and_acronym":"NCT05918692 - COVALENT-103","lead_sponsor":"Biomea Fusion Inc.","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • FLT3 wild-type","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BMF-500"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-05-27"},{"id":"f66040f9-40e2-41bd-8c69-4d4ef3afbdf1","acronym":"COMMODORE","url":"https://clinicaltrials.gov/study/NCT03182244","created_at":"2021-01-18T15:41:35.073Z","updated_at":"2024-07-02T16:35:01.009Z","phase":"Phase 3","brief_title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation","source_id_and_acronym":"NCT03182244 - COMMODORE","lead_sponsor":"Astellas Pharma Inc","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • etoposide IV • mitoxantrone • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 276","initiation":"Initiation: 01/15/2018","start_date":" 01/15/2018","primary_txt":" Primary completion: 12/25/2023","primary_completion_date":" 12/25/2023","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-05-24"},{"id":"7b7c91a6-9486-4633-b3e2-ffef9fa008f4","acronym":"ADMIRAL","url":"https://clinicaltrials.gov/study/NCT02421939","created_at":"2021-01-17T17:23:13.438Z","updated_at":"2024-07-02T16:35:01.814Z","phase":"Phase 3","brief_title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","source_id_and_acronym":"NCT02421939 - ADMIRAL","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • idarubicin hydrochloride • mitoxantrone • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 371","initiation":"Initiation: 10/20/2015","start_date":" 10/20/2015","primary_txt":" Primary completion: 09/17/2018","primary_completion_date":" 09/17/2018","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-23"},{"id":"a1b1a802-1353-41c5-80f6-98719e12dcd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05520567","created_at":"2022-08-30T20:55:48.582Z","updated_at":"2024-07-02T16:35:01.630Z","phase":"Phase 1/2","brief_title":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05520567","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/27/2023","start_date":" 01/27/2023","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2024-05-23"},{"id":"f8c1fb30-1e93-4d1d-b601-a40aa00e7c6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01995578","created_at":"2021-01-18T09:06:13.620Z","updated_at":"2024-07-02T16:35:02.011Z","phase":"Phase 2","brief_title":"Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse","source_id_and_acronym":"NCT01995578","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 09/27/2023","primary_completion_date":" 09/27/2023","study_txt":" Completion: 09/27/2023","study_completion_date":" 09/27/2023","last_update_posted":"2024-05-22"},{"id":"6705e7e6-5f76-403e-847f-2fbe43967ddb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241106","created_at":"2022-02-15T15:52:44.070Z","updated_at":"2024-07-02T16:35:03.973Z","phase":"Phase 2","brief_title":"A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05241106","lead_sponsor":"Tarapeutics Science Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HYML-122"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/29/2021","start_date":" 09/29/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-14"},{"id":"f65efc53-8b60-4d72-9e77-531f3964de27","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241093","created_at":"2022-02-15T15:52:43.789Z","updated_at":"2024-07-02T16:35:03.939Z","phase":"Phase 2","brief_title":"A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05241093","lead_sponsor":"Tarapeutics Science Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • HYML-122"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-14"},{"id":"7228addd-99a0-4c5e-a6f3-befe14f6f6de","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800210","created_at":"2023-04-05T14:03:37.666Z","updated_at":"2024-07-02T16:35:05.164Z","phase":"Phase 2","brief_title":"Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases","source_id_and_acronym":"NCT05800210","lead_sponsor":"University of Florida","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • CBL mutation • Chr t(9;11)","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • CBL mutation • Chr t(9;11)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/03/2024","start_date":" 05/03/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-05-08"},{"id":"264c1f17-e960-45e7-a8ad-1364b1706dfb","acronym":"NKX101-101","url":"https://clinicaltrials.gov/study/NCT04623944","created_at":"2022-04-15T16:52:42.805Z","updated_at":"2024-07-02T16:35:10.692Z","phase":"Phase 1","brief_title":"NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS","source_id_and_acronym":"NCT04623944 - NKX101-101","lead_sponsor":"Nkarta Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • decitabine • fludarabine IV • NKX101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 09/21/2020","start_date":" 09/21/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2039","study_completion_date":" 07/01/2039","last_update_posted":"2024-04-09"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"29adfbf7-ec59-401a-b21b-e4307b0a528a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03591510","created_at":"2021-01-18T17:39:51.327Z","updated_at":"2024-07-02T16:35:11.198Z","phase":"Phase 2","brief_title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","source_id_and_acronym":"NCT03591510","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • midostaurin • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 08/18/2025","primary_completion_date":" 08/18/2025","study_txt":" Completion: 02/15/2029","study_completion_date":" 02/15/2029","last_update_posted":"2024-04-05"},{"id":"e90cec53-ae6c-493e-9af7-3f156a05c47e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02400281","created_at":"2021-01-18T11:27:08.882Z","updated_at":"2024-07-02T16:35:13.589Z","phase":"Phase 1/2","brief_title":"Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients","source_id_and_acronym":"NCT02400281","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • etoposide IV • crenolanib (ARO-002) • idarubicin hydrochloride • mitoxantrone • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 07/15/2020","primary_completion_date":" 07/15/2020","study_txt":" Completion: 07/15/2020","study_completion_date":" 07/15/2020","last_update_posted":"2024-03-20"},{"id":"7e180e9a-1ded-4851-881d-ffda6c389c90","acronym":"NCI-2019-04959","url":"https://clinicaltrials.gov/study/NCT04140487","created_at":"2021-01-18T20:12:57.909Z","updated_at":"2024-07-02T16:35:14.512Z","phase":"Phase 1/2","brief_title":"Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm","source_id_and_acronym":"NCT04140487 - NCI-2019-04959","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 D835","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 D835"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-03-15"}]